LitAlert ~~ GeneLit.com

    • PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    • Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubinski J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK.
    • Breast Cancer Res. 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3.
    • Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
    • Chen G, Zhu YJ, Chen J, Miao F, Wu N, Song Y, Mao BB, Wang SZ, Xu F, Chen ZM.
    • Neoplasma. 2022 Oct 21:220721N738. doi: 10.4149/neo_2022_220721N738. Epub ahead of print.
    • Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
    • Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, Frampton GM, Das Thakur M, Oxnard GR, Tukachinsky H.
    • JCO Precis Oncol. 2022 Oct [20];6:e2200261. doi: 10.1200/PO.22.00261.
    • Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
    • O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
    • Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance.
    • Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G.
    • Expert Opin Pharmacother. 2022 Oct 21. doi: 10.1080/14656566.2022.2139176. Epub ahead of print.
    • Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
    • Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
    • Fam Cancer. 2022 Oct 20. doi: 10.1007/s10689-022-00317-w. Epub ahead of print.
    • Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
    • Kwon JS, Tinker AV, Santos J, Compton K, Sun S, Schrader KA, Karsan A.
    • JCO Precis Oncol. 2022 Oct [20];6:e2200033. doi: 10.1200/PO.22.00033.
    • SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer.
    • Flaherty C, DiSilvestro PA.
    • OncLive. 2022 Oct 20.

    Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov . Accessed 2022 Oct 20.)

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 20.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 20.
    • Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
    • Zhang X, Huo X, Guo H, Xue L.
    • Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.
  • LitAlert ~~ GeneLit.com

    • SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer.
    • Flaherty C, DiSilvestro PA.
    • OncLive. 2022 Oct 20.

    Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov . Accessed 2022 Oct 20.)

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 20.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 20.
  • LitAlert ~~ GeneLit.com

    • Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
    • Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
    • Fam Cancer. 2022 Oct 20. doi: 10.1007/s10689-022-00317-w. Epub ahead of print.
    • Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
    • Kwon JS, Tinker AV, Santos J, Compton K, Sun S, Schrader KA, Karsan A.
    • JCO Precis Oncol. 2022 Oct [20];6:e2200033. doi: 10.1200/PO.22.00033.
    • SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer.
    • Flaherty C, DiSilvestro PA.
    • OncLive. 2022 Oct 20.

    Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov . Accessed 2022 Oct 20.)

    • Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
    • O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
    • Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.
    • Population genomic screening: Ethical considerations to guide age at implementation.
    • Spencer SJ, Fullerton SM.
    • Front Genet. 2022 Oct 4;13:899648. doi: 10.3389/fgene.2022.899648.
  • LitAlert ~~ GeneLit.com

    • Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
    • Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
    • Fam Cancer. 2022 Oct 20. doi: 10.1007/s10689-022-00317-w. Epub ahead of print.
    • Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
    • O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
    • Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    • Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubinski J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK.
    • Breast Cancer Res. 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3.
    • Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance.
    • Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G.
    • Expert Opin Pharmacother. 2022 Oct 21. doi: 10.1080/14656566.2022.2139176. Epub ahead of print.
    • APC germline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?
    • Vibert R, Le Gall J, Buecher B, Mouret-Fourme E, Bataillon G, Becette V, Trabelsi-Grati O, Moncoutier V, Dehainault C, Carriere J, Schwartz M, Suybeng V, Bieche I, Colas C, Vincent-Salomon A, Stoppa-Lyonnet D, Golmard L.
    • J Med Genet. 2022 Oct 21:jmedgenet-2022-108467. doi: 10.1136/jmg-2022-108467. Epub ahead of print.
    • Case report
    • Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    • O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, Swisher EM, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL.
    • Gynecol Oncol. 2022 Oct 20:S0090-8258(22)00575-3. doi: 10.1016/j.ygyno.2022.08.021. Epub ahead of print.

    Identifier: NCT01968213: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3). (ClinicalTrials.gov . Accessed 2022 Oct 22.)

    • Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
    • Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, Frampton GM, Das Thakur M, Oxnard GR, Tukachinsky H.
    • JCO Precis Oncol. 2022 Oct [20];6:e2200261. doi: 10.1200/PO.22.00261.
    • Population genomic screening: Ethical considerations to guide age at implementation.
    • Spencer SJ, Fullerton SM.
    • Front Genet. 2022 Oct 4;13:899648. doi: 10.3389/fgene.2022.899648.